What You Should Know:
- Pangea Biomed, a leader in precision oncology, announced a significant breakthrough in its ENLIGHT cancer response predictor. A new study published in Nature Cancer demonstrates the effectiveness of their ENLIGHT-DP platform, revealing its ability to predict cancer treatment response across various types and drugs using only routine pathology slides.
- While these findings are promising, further validation and testing are planned for regulatory
Read More
Cancer Diagnostics
Color and Carrum Health Partner for End-to-End Cancer Care
What You Should Know:
- Color Health, a leader in comprehensive cancer care, and Carrum Health, known for their value-based cancer treatment programs form a startegic partnership to offer employers an end-to-end cancer program.
- By providing a seamless, cost-effective, and patient-centric experience, the end-to-end cancer program empowers employers to combat rising cancer rates and improve the overall health and well-being of their workforce.
The Deadly Reality of
Read More
OpenAI, Color Health Launch Cancer Copilot Tool To Expedite Cancer Treatment
What You Should Know:
- Cancer – the second leading cause of death in the United States – is a complex disease requiring timely diagnosis and treatment. Delays in either can significantly impact patient outcomes.
- Color Health, a company dedicated to improving access to healthcare, has partnered with OpenAI to pioneer a new solution: the copilot application. This innovative tool utilizes artificial intelligence (AI) to streamline cancer care and expedite treatment plans.
A
Read More
PathAI Unveils New AI-Powered Pathology Tools for Cancer Research
What You Should Know:
- PathAI, a global leader in AI-powered pathology, unveiled two novel AI products, PathExplore™ Immuno-Oncology Profiling (IOP) and IHC Explore1™ to empower cancer drug developers and clinical researchers with AI-powered insights.
- The product pairing provides unprecedented single-cell and spatial resolution of
Read More
COTA and FDA Extend Collaboration to Advance Use of Real-World Data in Cancer Research
What You Should Know:
- COTA, a leader in real-world data and analytics solutions, today announced a five-year extension of its research collaboration with the U.S. Food and Drug Administration's (FDA) Oncology Center of Excellence (OCE).
- The five-year extension builds upon a successful partnership established in 2018 and signifies a continued commitment to utilizing real-world data (RWD) to enhance cancer treatment and regulatory decisions.
Building on a Successful
Read More
VieCure Streamlines Cancer Care with Integrated E-Prescribing and Medication Management
What You Should Know:
- VieCure, a leading cancer care company, announced today that it's integrating DrFirst's e-prescribing and medication management solutions into its clinical decision support system.
- VieCure is a well-established point-of-care intelligence system specifically designed for community oncologists. Utilizing artificial intelligence (AI), patient data, and a comprehensive oncology knowledge base, VieCure generates personalized treatment plans for cancer
Read More
Culmination Bio, BillionToOne Partner to Validate Cancer Diagnostics
What You Should Know:
Culmination Bio, a data and technology company combining clinical and biospecimen data, announced a partnership with BillionToOne, Inc., a next-generation molecular diagnostics company with a mission to create powerful and accurate tests that are accessible to all.Culmination Bio and BillionToOne are working together to leverage their respective strengths in order to facilitate the development and validation of robust and impactful oncology
Read More
American Cancer Society, Color Health Expand Cancer Care Program for Employers and Unions
What You Should Know:
- The American Cancer Society (ACS) and Color Health announced today a significant expansion of their existing program, creating a first-of-its-kind comprehensive cancer solution for employers and labor unions. This enhanced program goes beyond screening and prevention to support employees and members throughout all stages of the cancer journey.
- The expanded program builds upon the existing collaboration between ACS and Color Health, which has already provided
Read More
Lunit Expands AI-powered Cancer Screening Solution to France and Portugal
What You Should Know:
- Lunit (KRX:328130.KQ), a provider of AI-powered cancer diagnostics and therapeutics solutions, announced today two significant commercial agreements that mark its continued European expansion.
- These strategic deals will bring Lunit's AI-powered cancer screening solution to healthcare providers in France and Portugal, aiding in the fight against cancer.
TeleDiag and Lunit Partner to Improve Lung Cancer Detection in France
Lunit has partnered with TeleDiag,
Read More
6 Ways AI is Impacting Cancer Diagnosis, Treatment and Patient Outcomes in 2024
Artificial intelligence (AI) technology is set to transform the field of diagnostics, similar to how X-rays and genetic tests revolutionized healthcare in the past. Reshaping routine diagnostic procedures and treatment decisions and propelling pharmaceutical and research domains into new realms, AI offers significant benefits to clinicians, healthcare systems, researchers, and, most importantly, patients. This is particularly evident in cancer diagnosis and treatment across six key areas:
1.
Read More
